DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(COMPLETED)

Information source: Schering-Plough
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Asmanex Twisthaler (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Schering-Plough

Official(s) and/or principal investigator(s):
Steven Weinstein, MD, Principal Investigator, Affiliation: Allergy & Asthma Specialists Medical Group in Huntington Beach, CA


This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) PM compared with "Asmanex" Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in FEV1 from Baseline to the end of treatment period (Week 12 or end of the study).

Clinical Details

Official title: A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With Mild/Moderate Persistent Asthma With Asmanex Twisthaler 220 Mcg QD PM Versus "Asmanex" Placebo QD PM

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Subjects must demonstrate their willingness to participate in the study and comply

with its procedures by signing a written informed consent.

- Must be 18-75 years of age, of either sex and any race.

- Must have a diagnosis of asthma for >= 12 months.

- Must be considered as having mild persistent or moderate persistent asthma.

- Prior to Screening subjects must be using either low or moderate doses of an inhaled

corticosteroid (ICS), with a short-acting beta-2 agonist (SABA) as needed (prn), or a SABA as necessary as monotherapy, for asthma control. Subjects who are using a combination ICS plus long-acting beta-2 agonist (LABA) medication, such as Advair 100/50, must be changed to treatment with fluticasone propionate (FLOVENT HFA 110 mcg twice daily [BID]) at least 30 days prior to the start of Run-In Period. Subjects who are using LABA as monotherapy must be switched to SABA prn for at least 5 days prior to the start of Run-In Period.

- If the subject had been using a leukotriene receptor antagonist (LTRA), he/she must be

off treatment with the LTRA for at least 14 days prior to the Baseline Visit.

- Must have an FEV1 >= 65% but <= 85% of predicted normal value at Visit 1 (Screening

Visit) and at Visit 3 (Baseline Visit) when SABAs have been withheld for at least 6 hours.

- Must demonstrate an increase of absolute FEV1 of >= 12% with an absolute volume

increase of at least 200 mL at the Screening Visit or have documentation of FEV1 reversibility of >= 12% within 2 years prior to the Screening Visit. FEV1 reversibility testing should be done after withholding inhaled SABA medication for at least 6 hours.

- Subjects must have a frequency of asthma score of at least 3 (at least 2 symptoms);

frequency of bronchodilator use score of at least 3 at the Screening Visit.

- Must have a TASS of at least 6 on 8 or more of the 15 AM and PM recordings during the

7 day Run-in period and the AM of the Baseline Visit (Visit 3).

- At the Screening Visit, subjects must complain of sleep disturbance and must have: a)

a score of >= 2 on the interference with sleep rating scale (recall over the past 7 days/ >= 1 night) and b) a score at least 30 on the MOS-SS Sleep Disturbance Sleep Scale (recall over the past 7 days).

- At the Baseline Visit, subjects must complain of sleep disturbance and must have: a) a

score of >= 2 on interference with sleep rating scale (recorded in a diary during the 7 day Run-In Period/ >= 1 night) and b) a score of at least 30 on the MOS-SS Sleep Problems Index II (SLP 9) and at least 30 on the Daytime Somnolence Sleep Scale.

Exclusion Criteria:

- Is a female who is pregnant, or intends to become pregnant during the study.

- Is nursing, or intends to be nursing during the study or within 30 days after study


- Has participated in any clinical trial within the last 30 days or in a clinical trail

that involved antibodies for asthma or rhinitis within 3 months prior to Randomization (Visit 3).

- Has had an unscheduled physician or clinic visit (due to exacerbation of asthma)

within 1 month prior to Randomization (Visit 3).

- Has been treated in the emergency room or admitted to the hospital due to exacerbation

of asthma on two or more occasions within the 12 months prior to Randomization (Visit 3).

- Has used >12 puffs of rescue SABAs or 2 treatments with a nebulized beta-2-agonist per

day on 2 consecutive days within 4 weeks prior to Randomization (Visit 3).

- Required more than 2 courses of oral/systemic corticosteroids for asthma control

within 12 months prior to Randomization (Visit 3).

- Has a history of sleep disorders, including narcolepsy, insomnia, daytime somnolence,

or use of medications that affect alertness or sleep.

- Has sleep apnea, obstructive sleep apnea-hypopnea syndrome, or is being treated with

CPAP or Bi-PAP, or is receiving oxygen by inhalation day or night.

- Is allergic to corticosteroids, SABAs, or LABAs.

- Required ventilator support for respiratory failure secondary to their asthma within

the last 10 years.

- Has symptomatic allergic rhinitis (total nasal and non-nasal symptom severity score >=

4) noted at the Screening and Baseline Visits (Visits 1, 2, and 3). (During any phase of the study, subjects who become symptomatic with allergic rhinitis can be treated with a nonsedating antihistamine and/or inhaled nasal corticosteroid. Allergic rhinitis severity should be rated and the score recorded in the diary at the initiation of this illness.

- nasal signs/symptoms include nasal congestion/stuffiness, rhinorrhea, nasal

itching, sneezing; non-nasal signs/symptoms include eye tearing, eye itching, eye redness, itching ears (palate); severity rating: 0 = none to 3 = severe

- Has a Body-Mass-Index (BMI) greater than 35.

Locations and Contacts

Additional Information

Starting date: September 2006
Last updated: August 22, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015